Chest Medicine (all articles)
Manual prone positioning in adults: reducing the risk of harm through evidence-based practices
2 Jun, 2023 | 12:14h | UTCNews Release: New guidance on manual prone positioning for patients with ARDS – American Association of Critical-Care Nurses
RCT | Dupilumab improves lung function and reduces exacerbations in COPD patients with elevated eosinophils
1 Jun, 2023 | 12:20h | UTCDupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary: Dupilumab Improves Outcomes for COPD, Type 2 Inflammation in Randomized Trial – HCP Live
Commentary on Twitter
Presented at #ATS2023: In the BOREAS trial, dupilumab resulted in a lower annualized rate of exacerbations than placebo among patients with COPD and an elevated blood eosinophil count. Full trial results: https://t.co/9IWZr3YqsN
— NEJM (@NEJM) May 21, 2023
M-A | Noninvasive ventilation in patients with acute hypoxemic respiratory failure
1 Jun, 2023 | 12:11h | UTC
Cluster RCT | Point-of-care CRP testing cuts antibiotic prescriptions in respiratory illnesses in primary care
1 Jun, 2023 | 11:58h | UTCCommentary: Use of CRP testing reduced antibiotics for respiratory infections, trial finds – CIDRAP
RCT | P2Y12 inhibitors don’t improve outcomes in critically ill COVID-19 patients
31 May, 2023 | 14:13h | UTCSee also: Visual Abstract
Cohort study | Airway-occluding mucus plugs in chest CT linked to higher mortality rates in COPD patients
29 May, 2023 | 11:10h | UTCAirway-Occluding Mucus Plugs and Mortality in Patients With Chronic Obstructive Pulmonary Disease – JAMA (free for a limited period)
News Release: Study linking mucus plugs and COPD mortality could help save lives – Brigham and Women’s Hospital
Ventilator associated tracheobronchitis and pneumonia: one infection with two faces
23 May, 2023 | 12:49h | UTC
M-A | Risk and benefits of wakefulness-promoting drugs in obstructive sleep apnea patients
23 May, 2023 | 12:43h | UTCComparative Efficacy and Safety of Wakefulness-Promoting Agents for Excessive Daytime Sleepiness in Patients With Obstructive Sleep Apnea: Systematic Review and Network Meta-analysis – Annals of Internal Medicine (link to abstract – $ for full-text)
News Release: Researchers find best treatment for excessive daytime sleepiness – McMaster University
Review | The esophageal balloon for respiratory monitoring in ventilated patients
23 May, 2023 | 12:40h | UTC
M-A | Timing of symptomatic venous thromboembolism after surgery
18 May, 2023 | 13:45h | UTC
Practice Guidance | Differential diagnosis of suspected COPD exacerbations in the acute care setting
15 May, 2023 | 13:26h | UTC
Commentary on Twitter
Differential Diagnosis of Suspected Chronic Obstructive Pulmonary Disease Exacerbations in the Acute Care Setting: Best Practice
? Open Access
? https://t.co/aPiT06E2g4 pic.twitter.com/kF40aSS7Oo— ATS Blue Journal (@ATSBlueEditor) May 12, 2023
RCT | Rivaroxaban doesn’t reduce thrombotic events, hospitalization, or death in outpatients with COVID-19
15 May, 2023 | 13:19h | UTCSummary: The PREVENT-HD trial, a double-blind, placebo-controlled randomized study, was conducted to evaluate the effectiveness of prophylactic anticoagulation in reducing venous and arterial thrombosis, hospitalization, and death in nonhospitalized patients with symptomatic COVID-19 and at least one thrombosis risk factor. The trial took place between August 2020 and April 2022 across 14 US integrated healthcare delivery networks, with 1,284 patients enrolled and randomly assigned to receive either 10 mg of oral rivaroxaban or placebo daily for 35 days.
However, the study was terminated prematurely due to enrollment challenges and lower-than-expected event rates. The primary efficacy outcome, a composite of various hazardous events, occurred in 3.4% of the rivaroxaban group and 3.0% of the placebo group, with no significant difference between the two groups (hazard ratio, 1.16 [95% CI, 0.63–2.15]; P=0.63). No critical-site or fatal bleeding was observed, and only one patient in the rivaroxaban group experienced a major bleed.
In conclusion, rivaroxaban prescribed for 35 days in nonhospitalized patients with symptomatic COVID-19 at risk for thrombosis does not appear to reduce the composite end point of venous and arterial thrombotic events, hospitalization, and death. The study’s premature termination and lower-than-expected event rates may limit the generalizability of these findings.
Commentary on Twitter
#OriginalArticle: In this #RCT, Rivaroxaban did not appear to reduce a composite endpoint of venous and arterial thrombotic events, hospitalization, and death among non‐hospitalized patients with symptomatic COVID‐19 #AHAJournals https://t.co/PhdXnTJ0V9 pic.twitter.com/f04uYu2M5f
— Circulation (@CircAHA) May 10, 2023
RCT | Novel autotaxin inhibitor Ziritaxestat shows no benefit for idiopathic pulmonary fibrosis
15 May, 2023 | 13:08h | UTCZiritaxestat, a Novel Autotaxin Inhibitor, and Lung Function in Idiopathic Pulmonary Fibrosis: The ISABELA 1 and 2 Randomized Clinical Trials – JAMA (free for a limited period)
Review | Awake prone positioning in acute hypoxemic respiratory failure
15 May, 2023 | 12:56h | UTCAwake prone positioning in acute hypoxaemic respiratory failure – European Respiratory Review
M-A | Effectiveness of diaphragmatic ultrasound as a predictor of successful weaning from mechanical ventilation
15 May, 2023 | 12:46h | UTC
Post-pneumonectomy syndrome: a systematic review of the current evidence and treatment options
15 May, 2023 | 12:45h | UTC
ERS statement on airway clearance techniques in adults with bronchiectasis
12 May, 2023 | 13:42h | UTC
Review | Progress in the treatment of acute pulmonary embolism and chronic thrombo-embolic pulmonary hypertension/disease
12 May, 2023 | 13:24h | UTCSee all articles in the series here
RCT | Early NIV and HFNO therapy for preventing endotracheal intubation in hypoxemic blunt chest trauma patients
10 May, 2023 | 15:48h | UTC
M-A | Effects of different types of early rehabilitation on ventilator weaning among patients in the ICU
10 May, 2023 | 15:34h | UTC
M-A | Clinical profile and outcome of isolated pulmonary embolism
10 May, 2023 | 15:27h | UTC
Review | Therapeutics for COVID-19
9 May, 2023 | 14:53h | UTCTherapeutics for COVID-19 – Nature Microbiology
Commentary on Twitter
?New Perspective out now:
Therapeutics for COVID-19
By Sima Toussi, Jennifer Hammond, Brian Gerstenberger & Annaliesa Andersonhttps://t.co/WNJzkFMFuF
— Nature Microbiology (@NatureMicrobiol) May 5, 2023
USPSTF Statement | Asymptomatic adults at increased risk should be screened for latent TB
5 May, 2023 | 15:34h | UTCEvidence Report: Screening for Latent Tuberculosis Infection in Adults: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force – JAMA
Editorials:
Screening for Latent Tuberculosis Infection – JAMA Network Open
JAMA Patient Page: Screening for Latent Tuberculosis
Author Interview: USPSTF Recommendation: Screening for Latent Tuberculosis Infection in Adults
Brief Review | Management of latent tuberculosis infection
5 May, 2023 | 15:32h | UTCManagement of Latent Tuberculosis Infection – JAMA (free for a limited period)
Consensus Statement | Venovenous extracorporeal membrane oxygenation (ECMO) for COVID-19 with severe ARDS
5 May, 2023 | 15:19h | UTC